PHAGE THERAPY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

The global phage therapy market is estimated to be valued at USD 1.34 Bn in 2025 and is expected to reach USD 2.03 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032. The global phage therapy market represents a revolutionary approach to combating bacterial infections through the therapeutic application of bacteriophages, naturally occurring viruses that specifically target and destroy bacterial pathogens. As antibiotic resistance continues to escalate worldwide, phage therapy has emerged as a promising alternative treatment modality, offering precision medicine capabilities that can address multidrug-resistant bacterial infections where conventional antibiotics have failed. This innovative therapeutic approach leverages the natural predator-prey relationship between bacteriophages and bacteria, utilizing these microscopic entities to selectively eliminate harmful bacterial strains while preserving beneficial microbiota.

The market encompasses various phage-based products, including personalized phage cocktails, standardized therapeutic formulations, and diagnostic tools for bacterial identification and susceptibility testing. Phage therapy applications span across multiple medical domains, including treatment of chronic wound infections, respiratory tract infections, urinary tract infections, and gastrointestinal disorders. The growing recognition of phage therapy's potential by regulatory bodies, coupled with increasing investment in research and development activities, has positioned this market for substantial growth. Healthcare providers and pharmaceutical companies are increasingly exploring phage therapy as a viable solution to address the global antimicrobial resistance crisis, driving innovation in manufacturing processes, quality control standards, and clinical trial methodologies to establish robust therapeutic protocols.

Market Dynamics

The global phage therapy market is experiencing significant growth momentum driven by multiple compelling factors, with the most prominent being the escalating global crisis of antibiotic resistance that has rendered many conventional treatments ineffective against multidrug-resistant bacterial infections. The World Health Organization's classification of antimicrobial resistance as one of the top ten global public health threats has accelerated research investments and regulatory support for alternative therapeutic approaches, positioning phage therapy as a critical solution. Increasing prevalence of hospital-acquired infections, chronic wounds, and bacterial biofilm-associated diseases further amplifies market demand, as healthcare providers seek targeted treatments with minimal side effects. Growing awareness among healthcare professionals and patients about personalized medicine approaches, combined with successful clinical case studies demonstrating phage therapy efficacy, continues to drive market adoption. However, the market faces significant restraints including complex regulatory frameworks that lack standardized approval pathways for phage-based therapeutics, creating lengthy and expensive development timelines.

Manufacturing challenges related to phage stability, quality control, and large-scale production processes pose additional barriers to commercialization. Limited clinical trial data and the need for extensive safety and efficacy studies across diverse bacterial strains constrain rapid market expansion. Furthermore, high development costs, intellectual property complexities, and the requirement for specialized storage and distribution infrastructure create entry barriers for smaller companies. Nevertheless, substantial opportunities exist through strategic partnerships between pharmaceutical companies and biotechnology firms, government funding initiatives supporting antimicrobial resistance research, and expanding applications in veterinary medicine and agriculture. The emergence of phage banks, advances in synthetic biology enabling engineered phages, and growing acceptance of combination therapies integrating phages with traditional antibiotics present lucrative growth avenues for market participants.

Key Features of the Study

• This report provides in-depth analysis of the global phage therapy market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global phage therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Armata Pharmaceuticals Inc, BiomX Inc, Pherecydes Pharma SAS, Intralytix Inc, Locus Biosciences Inc, Nextbiotics Ltd, Proteon Pharmaceuticals SA, iNtRON Biotechnology Co Ltd, Micreos BV, Eligo Bioscience SA, FAGŌTAC Therapeutics (or Fagoterapia), Evolution Biotechnologies Inc, Tol ka AI Therapeutics Inc, PrecisionPhage Oy, and Obulytix Inc
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global phage therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global phage therapy market

Market Segmentation

•  Product Insights (Revenue, USD Bn, 2020 - 2032)
  • Monophage therapy
  • Phage cocktails
  • Engineered/recombinant phages
  • Phage‑derived enzymes (e.g., endolysins)
  • Combination products (phage + antibiotic or adjunct)
•  Target Pathogen Insights (Revenue, USD Bn, 2020 - 2032)
  • Gram‑negative bacteria
    • Escherichia coli
    • Pseudomonas aeruginosa
    • Salmonella spp.
    • Klebsiella pneumoniae
    • Other Gram‐negative bacteria
  • Gram‑positive bacteria
    • Staphylococcus aureus
    • Streptococcus spp.
    • Other Gram‐positive bacteria
    • Mixed/other pathogens
•  Disease Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Urinary tract infections (UTIs)
  • Skin and wound infections
  • Bone and joint/implant‑associated infections
  • Respiratory tract infections (including cystic fibrosis)
  • Gastrointestinal infections
  • Bloodstream/sepsis infections
  • Biofilm‑related chronic infections
  • Other indications
•  Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Topical/dermal
  • Injectable/intravenous (IV/IM)
  • Inhalation/nebulized
  • Local instillation (e.g., bladder, wound cavity)
  • Other routes
•  End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals and specialty clinics
  • Research institutes and academic centers
  • Ambulatory care/outpatient clinics
  • Others (Veterinary clinics)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Armata Pharmaceuticals Inc
  • BiomX Inc
  • Pherecydes Pharma SAS
  • Intralytix Inc
  • Locus Biosciences Inc
  • Nextbiotics Ltd
  • Proteon Pharmaceuticals SA
  • iNtRON Biotechnology Co Ltd
  • Micreos BV
  • Eligo Bioscience SA
  • FAGŌTAC Therapeutics (or Fagoterapia)
  • Evolution Biotechnologies Inc
  • Tol ka AI Therapeutics Inc
  • PrecisionPhage Oy
  • Obulytix Inc